EQA Reference No: 020  
UKNEQAS for Blood Coagulation

Royal Hallamshire Hospital STH NHS Foundation Trust  
3rd Floor Pegasus House  
463a Glossop Road  
Sheffield  
South Yorkshire  
S10 2QD

Accredited against the requirements of  
*Standards for EQA Schemes in Laboratory Medicine*

<table>
<thead>
<tr>
<th>Name of Scheme</th>
<th>Analytes</th>
<th>Location (if different to centre address)</th>
</tr>
</thead>
</table>
| UKNEQAS for Blood Coagulation Level 1 and Level 2 (Main Programme) | Level 1: International Normalised Ratio (INR) based on:  
 a) Quick’s one stage method  
 b) Capillary reagent method  
 Prothrombin Time (diagnosis)  
 Activated Partial Thromboplastin Time (APTT)  
 Thrombin Time  
 Heparin Dosage Assessment (HDA)  
 Heparin Assay  
 Fibrinogen determination  
 D-Dimer  
 Lupus Anticoagulant screening | |
### EQA Schedule of Accreditation

**issued by Clinical Pathology Accreditation (UK) Ltd.**

21-47 High Street, Feltham, Middlesex, TW13 4UN

<table>
<thead>
<tr>
<th>Factor VIII</th>
<th>Factor IX</th>
<th>Factor X</th>
<th>Factor XI</th>
<th>Factor XII</th>
<th>Factor XIII screen test/assay</th>
<th>Factor VIII Inhibitor determination</th>
</tr>
</thead>
<tbody>
<tr>
<td>Assays for:</td>
<td>vWF</td>
<td>Antigen and vWF</td>
<td>RiCoF</td>
<td>Antithrombin antigen and activity</td>
<td>Protein C antigen and activity</td>
<td>Protein S total and free antigen</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Protein S activity</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Activated Protein C Resistance</td>
</tr>
</tbody>
</table>

### Near Patient/Point of Care testing EQA Scheme

- Prothrombin Time (PT)
- International Normalised Ratio (INR) for oral anticoagulant control by POCT methods

### Factor V Leiden / Molecular Genetics of Thrombophilia

- Molecular Genetics of Thrombophilia investigations
- Factor V Leiden screening
- Prothrombin 20210a mutation screening

### Blood Coagulation Homocysteine Assay

- Plasma Homocysteine

### Haemophilia Genetics

- Surveys will comprise material for investigation together with clinical details and for each survey – participants are requested to provide a detailed report complying with the Clinical and Molecular Genetics Society.
- Participants are also encouraged to use the nomenclature recommended by the Human Genome Variation Society.
A closing date for return of results will be given normally six weeks after the date of distribution. Individual reports based on the analysis of returned results will be sent to the participants as soon as possible after the survey closing date.